OnThePharm thinks so. The GLP-1 based therapies are an exciting new class of diabetes medications. So far, Byetta has worked well for my patients – the jury is still out with Januvia. Merck certainly hopes that Januvia will rescue them.
Related posts:
- Is Januvia next?
- Januvia and Stevens-Johnson
- Are Actos and Avandia to blame for rising diabetes costs?
- Medication refills
- Alli is here
- Prescription medication pay for performance, and the rationale behind it
- 2007 Diabetes Year in Review
KevinMD.com on Facebook
Comments on this entry are closed.